Diabetes management is the next frontier
Type 2 diabetes (T2D) is one of the most prevalent chronic conditions in the general U.S. population, ranking alongside hypertension (high blood pressure), high cholesterol, and arthritis as one of the four most common chronic diseases. At this point in time, diabetes cannot be completely cured. The four main components of the current approach that […]
Could Tirzepatide be a “Cure” for Type 2 Diabetes?
Normoglycemia is a term that’s drawing a lot of attention in medical circles lately, not because it is new, but because suddenly it seems possible that people who have a medical condition that has always been considered “incurable” may be able to achieve the normal state, which is what normoglycemia is. The thing that’s drawing […]
A Smarter Way to Understand Prediabetes
Both prediabetes and diabetes are very common conditions. Studies have shown that about 38 million adults in the US have been diagnosed as diabetics, which is nearly 15% of the US adult population. Prediabetes is far more common. Reliable estimates put the numbers at just below 100 million adults in the US, although the majority […]
Is Rybelsus the same as semaglutide?
There has been a tidal wave of interest in the new “wonder drugs” that are based on chemicals called glucagon-like peptide-1 receptor agonists (GLP-1RA), which have revolutionized treatments of a wide range of potentially serious diseases. Many people are now familiar with the common terms associated with these new treatments, such as Ozempic, Mounjaro, semaglutide […]
GLP-1 Medications and Aging: Benefits and Risks for Older Adults
GLP-1 medications like Ozempic and Mounjaro are gaining popularity among older adults not only for managing diabetes but also for their potential anti-aging effects. But alongside the benefits, there are real risks, especially for those over 65. Understanding both sides is key to making informed decisions that support healthy aging. GLP-1 drugs revolutionized the world […]
Common GLP-1 Side Effects Made Simple
Drugs like Ozempic, Wegovy, Zepbound, and Mounjaro have changed the way doctors manage type 2 diabetes and obesity. These medications, called GLP-1 receptor agonists, help the body produce more insulin after meals, slow down digestion, and reduce appetite. The results can be dramatic, including weight loss, improved blood sugar control, and a reduced risk of heart disease. But there’s […]
Wegovy is Being Tested to Treat Severe Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NASH), affects nearly one-third of the US population (over 100 million people). Obesity is thought to be the most common cause. In some cases, MASLD can develop into a more serious condition called metabolic dysfunction-associated steatohepatitis (MASH). Both conditions develop when the liver […]
Can GLP-1s Help Prevent Glaucoma?
A new study by ophthalmologists suggests that drugs based on GLP-1 receptor agonists (GLP-1RAs), like Wegovy, Mounjaro, Saxenda, Rybelsus, and Ozempic, which were originally designed to control blood sugar levels in people with type 2 diabetes, may also protect against a number of eye conditions. Research into the use of GLP-1 drugs for glaucoma found […]
GLP-1s Join the Fight Against Addiction
At this year’s American Society of Addiction Medicine (ASAM) Annual Conference, a big focus was on GLP-1 receptor agonists (GLP-1 RAs). These drugs, commonly used to treat diabetes, have also been found to aid in weight loss, leading to their consideration as a treatment for obesity. However, GLP-1s aren’t just for weight loss or type […]
New Hope for Lowering the Risk of Dementia
Just this week, I was asked by a colleague to comment on a fairly technical article, and I was struck by the exact wording used in its opening question: Are cardioprotective glucose-lowering agents associated with reduced risk of dementia? I spend a fair bit of time reviewing and replying to questions and requests from our […]
